Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

JulieAnn Rader, Mike R. Russell, Lori S. Hart, Michael S. Nakazawa, Lili T. Belcastro, Daniel Martínez, Yimei Li, Erica L. Carpenter, Edward F. Attiyeh, Sharon J. Diskin, Sunkyu Kim, Sudha Parasuraman, Giordano Caponigro, Robert W. Schnepp, Andrew Wood, Bruce Pawel, Kristina A. Cole, John M. MarisClinical 2013 · DOI

Abstract

Taken together, our data show that LEE011 is active in a large subset of neuroblastoma cell line and xenograft models, and supports the clinical development of this CDK4/6 inhibitor as a therapy for patients with this disease. Clin Cancer Res; 19(22); 6173-82. ©2013 AACR.
BibTeX
@inproceedings{rader2013dual,
  author = {JulieAnn Rader and Mike R. Russell and Lori S. Hart and Michael S. Nakazawa and Lili T. Belcastro and Daniel Martínez and Yimei Li and Erica L. Carpenter and Edward F. Attiyeh and Sharon J. Diskin and Sunkyu Kim and Sudha Parasuraman and Giordano Caponigro and Robert W. Schnepp and Andrew Wood and Bruce Pawel and Kristina A. Cole and John M. Maris},
  title = {{Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma}},
  booktitle = {Clinical},
  year = {2013},
  doi = {10.1158/1078-0432.ccr-13-1675},
}

Loading related content...

Figure